The 12th European Biosimilars Congress one of its remarkable Pharmaceutical conferences, to be held during April 15-16, 2019 in Berlin, Germany. European Biosimilars Congress is a global annual event. This European Biosimilars Congress 2019 will bring together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.

At Euro Biosimilars 2019 meet your target audiences from around the world focused on learning about biologics and Biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and Biosimilars community.

• Directors, CEO’s of Organizations
• Business Development Managers
• Chief Scientific Officers
• R&D Researchers from Biosimilar and Bioslogics Industries
• Professors, Associate Professors, Assistant Professors
• PhD Scholars
• Patent Attorneys
• Intellectual Property Attorneys
• Investment Analysts
• Association, Association presidents and professionals
• Noble laureates in Health Care and Medicine
• Bio instruments Professionals
• Bio-informatics Professionals
• Software development companies
• Research Institutes and members
• Supply Chain companies
• Manufacturing Companies
• CRO and DATA management Companies
• Training Institutes
• Business Entrepreneurs

Track 1: Current Challenges in Developing Biosimilars

Track 2: Analytical Strategies for Biosimilars

Track 3: Intellectual Property Rights

Track 4: Biological Medicine

Track 5: Emerging Biosimilars in Therapeutics

Track 6: Innovative Clinical Approach in Biosimilars

Track 7: Regulatory updates on Biosimilars

Track 8: Biosimilars Development in Markets

Track 9: Biosimilars Approval to Biogenerics in Clinical Practice

Track 10: Biopharmaceutical Informatics

Track 11: Consequences of Brexit on Biosimilars

Track 12: BCS and IVIVC Based Biowaivers

Track 13: Biosimilars Market and Cost Analysis

Track 14: Challenges in Biosimilars Pharmacovigilance

Track 15: Legal Issues and BPCI Act

Track 16: Formulation Strategies for Follow-on Biologics

Track 17: Current Agency Expectations for Approval for Biosimilars

Track 18: Biosimilars Research Pipeline

Track 19: Globalization of Biosimilars

Track 20: Drug Delivery and Development

Track 21: Monoclonal Antibody Biosimilars

Track 22: USFDA Approved Biosimilars

+Attend Now

+Attend Now